Detalhe da pesquisa
1.
Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study.
Neurourol Urodyn
; 39(5): 1378-1386, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32383533
2.
Methods of sample size calculation in descriptive retrospective burden of illness studies.
BMC Med Res Methodol
; 19(1): 9, 2019 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30626343
3.
The economic burden of prematurity in Canada.
BMC Pediatr
; 14: 93, 2014 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24708755
4.
Comparing Preferences for Disease Profiles: A Discrete Choice Experiment from a US Societal Perspective.
Appl Health Econ Health Policy
; 22(3): 343-352, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38253973
5.
Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE).
BMC Health Serv Res
; 13: 454, 2013 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24176050
6.
The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia.
J Med Econ
; 25(1): 919-929, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35730362
7.
A Method for Reconstructing Individual Patient Data From Kaplan-Meier Survival Curves That Incorporate Marked Censoring Times.
MDM Policy Pract
; 7(1): 23814683221077643, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35128059
8.
Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.
Clin J Pain
; 38(11): 680-685, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125279
9.
SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada).
ERJ Open Res
; 8(3)2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171990
10.
Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant.
Adv Ther
; 38(10): 5209-5220, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34455556
11.
Health expenditures after first hospital admission for heart failure in Nova Scotia, Canada: a retrospective cohort study.
CMAJ Open
; 9(3): E826-E833, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34446462
12.
Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada.
Value Health
; 13(6): 703-11, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20561333
13.
Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC).
J Med Econ
; 23(10): 1123-1129, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32597288
14.
Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Hematology
; 25(1): 327-334, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32856539
15.
A review of published anticholinergic scales and measures and their applicability in database analyses.
Arch Gerontol Geriatr
; 87: 103885, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31155228
16.
Advanced Data Visualisation in Health Economics and Outcomes Research: Opportunities and Challenges.
Appl Health Econ Health Policy
; 17(4): 433-441, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31054095
17.
Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review.
Adv Ther
; 36(3): 548-562, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30715686
18.
The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature.
J Affect Disord
; 242: 195-210, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30195173
19.
The Association Between Overactive Bladder and Falls and Fractures: A Systematic Review.
Adv Ther
; 35(11): 1831-1841, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30255417
20.
Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.
PLoS One
; 12(10): e0180261, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28991893